Table 1.
Major clinical trials of the long course radiotherapy (LCRT) combined with immunotherapy for LARC.
| Study | Phase | No. | Features | Study design | Results |
|---|---|---|---|---|---|
| Voltage-A | Ib | 37 | III 23% |
|
pCR 30% |
| NSABP FR-2 | II | 45 | III 89% |
|
mNAR 12.03 pCR 22.2% cCR 31.1% |
| PANDORA | II | 55 | T3-4 95% N+ 79% |
|
pCR 32.7% MPR 25.5% |
| AVANA | II | 100 | III 94% |
|
pCR 23% MPR 60% |
| R-IMMUNE | Ib | 25 | III 92% |
|
pCR 24% |
| NRG -GI002 | II | 95 | High risk+ |
|
pCR 31.9% cCR 13.9% |
| PKUCH 04 | II | 25 | 76% N2 56% MRF+ |
|
pCR 33.3% cCR 16% MPR 25% |
| Changhai | II | 23 | Super-low cT2 56.5% cN0 69.6% |
|
cCR 43.5% ncCR 26.1% Anal preservation 95.5% CR 52.2% |
| Beijing Friendship | II | 12 | cT3N0 cT1-3N+ |
|
pCR 58.3% |